ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. Biotech Stocks, ETFs Due for Second Half Rallies
Beyond Basic Beta Channel
Share

Biotech Stocks, ETFs Due for Second Half Rallies

Tom LydonJul 11, 2022
2022-07-11

Biotechnology stocks and the related exchange traded funds are in a prolonged slump, and along the way, calls for rebounds have been plentiful. They’ve also proven inaccurate.

No, biotech stocks and ETFs such as the VanEck Vectors Biotech ETF (BBH B-) won’t be out of favor permanently. Pinpointing exactly when the group will materially recover, well, that’s another matter altogether. Still, there’s optimism that, with the current biotech slump more than a year old, which is lengthy by historical standards. Some market observers believe a turnaround may already be in the works.

“The sector is positioned well to outperform for a variety of fundamental reasons. Biotechs—along with many other areas of healthcare—are largely recession-resistant. With an almost 40% decline in the sector from last year’s high, we are likely to see increased takeover activity,” reports Andrew Addison for Barron’s.

Undoubtedly, consolidation speculation often tantalizes and disappoints biotech investors. Additionally, deal-making has been sluggish this year, but hope burns eternal, particularly amid recent news that Dow component Merck (NYSE:MRK) is moving on cancer biotech name Seagen (NASDAQ:SGEN) for $40 billion.

BBH, which tracks the MVIS US Listed Biotech 25 Index, allocates 5.33% of its weight to Seagen. That’s enough to have the ETF higher by almost 7% over the past week on the back of the Merck takeover rumor. Biotech stocks and BBH could also be beneficiaries of favorable technical tailwinds.

“Further evidence of the group’s strength is that volume flows have rocketed to new all-time highs (see above chart)—even as the Index is well below its 5500 price high from last year. This is evidence of strong buying pressure. I expect that biotechs are positioned to outperform the market for the balance of 2022,” says Addison in reference to a widely followed biotech index.

The ETF offers ample promise for long-term investors willing to wait out a BBH rebound. That potential could be amplified as biotech companies further refine advanced concepts, including precision medicine, platform-based therapeutics, new delivery methods, small molecules, immune-oncology, machine learning-based drug discovery, and more.

“Gene therapies have transformed patient treatment, offering, in some cases, excellent outcomes for genetic disorders. According to a McKinsey analysis of pharmaceutical industry data from Evaluate, roughly 400 gene therapies are currently in development; by 2025, they could comprise around 20 percent of new product launches. The field continues to evolve, with gene editing enabling permanent and precise genetic deletions and ex vivo modifications,” notes McKinsey.

For more news, information, and strategy, visit the Beyond Basic Beta Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X